RxDoctor Payments Data

Arun Raghupathy, MD

Interventional Cardiology · Larkspur, CANPI 1245358324

Payments from drug & device makers

$69,031in general payments, 2019–2025

Across 339 payments — averaging $203.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$52K
  • Abbott$8K
  • Edwards Lifesciences$5K
  • Medtronic$3K
  • Abiomed$384
  • Heartflow, Inc.$340
  • plus $430 from 13 others

What the payments were for

  • Consulting fees$4,32517%
  • Travel & lodging$8,64434%
  • Food & beverage$12,49349%
  • Education$150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$69,031 in reported general payments places this provider in the 80th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$303,427
Medicare patients
797
Services billed
2,730

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban342$420,388
XareltoRivaroxaban106$137,479
Repatha SureclickEvolocumab62$63,409
EntrestoSacubitril/Valsartan30$34,318
JardianceEmpagliflozin32$27,747
MultaqDronedarone Hcl12$24,526
BrilintaTicagrelor28$17,928
Repatha SyringeEvolocumab16$12,286
Atorvastatin Calcium705$8,500
Losartan Potassium464$6,476
Metoprolol Succinate349$5,445
Nebivolol Hcl41$4,838
Ezetimibe153$4,457
Dabigatran EtexilateDabigatran Etexilate Mesylate12$4,138
Rosuvastatin Calcium190$3,282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$43$137,479106 claims
NovartisEntresto$20$34,31830 claims
AstraZenecaBrilinta$14$17,92828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Larkspur

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →